* CorMedix Inc reported a quarterly adjusted loss of 5 cents per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -17 cents. The mean expectation of four analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -13 cents to -6 cents per share.
* Revenue was $11.46 million; analysts expected $10.84 million.
* CorMedix Inc's reported EPS for the quarter was a loss of 5 cents.
* The company reported a quarterly loss of $2.78 million.
* CorMedix Inc shares had risen by 60.5% this quarter and gained 244.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 34.8% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for CorMedix Inc is 13.50 This summary was machine generated from LSEG data October 30 at 03:12 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.10 -0.05 Beat
Jun. 30 2024 -0.25 -0.25 Met
Mar. 31 2024 -0.20 -0.25 Missed
Dec. 31 2023 -0.20 -0.26 Missed
Comments